Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from rat) |
Target | CD2 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
|
![]() ![]() |
Siplizumab (MEDI-507) is an investigational monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and has been tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.[1][2][3][4][5]
| |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular (initiation) |
| ||||||||||||||
Intracellular (reception) |
| ||||||||||||||
Extracellular |
| ||||||||||||||
Unsorted |
|
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
![]() | This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |